Qatar Cardiovascular Biorepository

The Qatar Cardiovascular Biorepository (QCBio) consists of plasma and DNA of Qatari patients with coronary heart disease (CHD) and age-, gender-, and ethnicity-matched controls. CHD cases include patients with acute coronary syndromes (myocardial infarction, unstable angina) identified in the cardiac catheterization laboratory/coronary care unit. Controls include blood donors who have no history of CHD.

Why QCBio ?

Coronary heart disease (CHD) poses a major health burden in the Gulf countries.

Knowledge of novel genetic and proteomic markers of CHD will provide more precise estimates of risk while defining the pathways important in individual patients, revealing new targets for intervention, and ultimately enabling an individualized approach to care.

We describe design of a biorepository with linkage to medical records to facilitate discovery of biomarkers for CHD.

  • IRB Approval:
    The study is approved by the HAMAD Medical Center IRB. Equipment and infrastructure is in place and recruitment has begun.
  • Patient Questionnaire:
    We have created a consent form and questionnaire in Arabic to obtain information on demographic factors, cardiovascular disease risk factors, and family history.
  • Laboratory Information Management System:
    We are using a LIMS for sample tracking and have set up this website to facilitate use of the samples.
  • Recruitment:
    Recruitment for the study is done by study coordinators. Sample processing, aliquoting and DNA extraction is done by technologists.

Goals

The goal of the Qatar Cardiovascular Biorepository (QCBio) is to archive plasma and DNA of 1000 Qatari patients with CHD and 1000 age-, gender-, and ethnicity-matched controls who have no history of CHD. Cases will include patients needing percutaneous intervention for symptomatic CHD or admitted with an acute coronary syndrome (myocardial infarction or unstable angina). Controls will be identified from the blood bank as adults who have no history of CHD. Relevant risk factors and comorbid conditions will be ascertained by electronic medical record (EMR)-based electronic phenotyping algorithms that include diagnosis and procedure codes, medication use, and laboratory data. We will include processes to promote use of the biorepository by Qatar investigators by facilitating access to the repository for biomarker research, while maintaining the highest ethical standards with emphases on patient confidentiality and stewardship of the biospecimens.

More

Why QCBio

Coronary heart disease (CHD) poses a major health burden in the Gulf countries. Knowledge of novel genetic and proteomic markers of CHD will provide more precise estimates of risk while defining the pathways important in individual patients, revealing new targets for intervention, and ultimately enabling an individualized approach to care. We describe design of a biorepository with linkage to medical records to facilitate discovery of biomarkers for CHD.

Goals of QCBio

The goal of the Qatar Cardiovascular Biorepository (QCBio) is to archive plasma and DNA of 1000 Qatari patients with CHD and 1000 age-, gender-, and ethnicity-matched controls who have no history of CHD. Cases will include patients needing percutaneous intervention for symptomatic CHD or admitted with an acute coronary syndrome (myocardial infarction or unstable angina). Controls will be identified from the blood bank as adults who have no history of CHD. Relevant risk factors and comorbid conditions will be ascertained by electronic medical record (EMR)-based electronic phenotyping algorithms that include diagnosis and procedure codes, medication use, and laboratory data. We will include processes to promote use of the biorepository by Qatar investigators by facilitating access to the repository for biomarker research, while maintaining the highest ethical standards with emphases on patient confidentiality and stewardship of the biospecimens.

IRB approval

We have obtained approval from the Hamad Medical Center IRB. Equipment and infrastructure is now in place and recruitment has begun.

Patient Questionnaire

We have created a consent form and questionnaire in Arabic to obtain information on demographic factors, cardiovascular disease risk factors, and family history.

Laboratory Information Management System (LIMS)

We will put in place a Laboratory Information Management System (LIMS) for sample tracking, set up a website for the study.

Recruitment

We have hired the technologist for sample processing, aliquoting, and DNA extraction; hired and trained the study coordinators who will recruit patients.


Research Papers

Symptomatic CHD

Cases will include patients needing percutaneous intervention for symptomatic CHD or admitted with an acute coronary syndrome

CHD History

Controls will be identified from the blood bank as adults who have no history of CHD

Phenotyping Algorithms

Risk factors and comorbid conditions will be ascertained by electronic medical record (EMR)-based electronic phenotyping algorithms

DNA Extraction

DNA will be extracted from lymphocytes. Plasma and serum will be stored at -80°


Welcome to QCBio Repository

Funded by the Qatar National Research Foundation
Help completing our research by attending survey
Take Survey